Eye Disease News and Research

RSS

Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

16 Jun 2010

UH, AOA partner to get the word out about summer eye care, protection against UVR

As summer approaches, most people step up skin protection from harmful ultraviolet rays, yet aren't as vigilant about their eyes. Optometrists at the University of Houston are involved in a campaign to change this way of thinking.

15 Jun 2010

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Researchers at the University of Oklahoma Health Sciences Center have found a way to use a radical new type of gene therapy to prevent blindness caused by retinitis pigmentosa, giving hope to the estimated 100,000 Americans who suffer from this debilitating disease.

14 Jun 2010

Researchers to present advanced treatment strategies for eye diseases at NEI symposium

The National Eye Institute (NEI), part of the National Institutes of Health (NIH), is bringing together premier researchers who translate molecular and genetic approaches from the laboratory to visual system diseases in the clinic.

11 Jun 2010

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the United States Food and Drug Administration (US FDA). The IND is for Can-Fite's lead compound, CF101, for the treatment of patients with psoriasis. This is the third US IND for CF101, and the fourth for Can-Fite.

8 Jun 2010

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that in collaboration with OXiGENE, Professor Gordon Rustin and colleagues from the Mount Vernon Cancer Research Centre, UK and other institutions in the United Kingdom, reported positive final data from an investigator-sponsored Phase 1 study of OXi4503 in patients with solid tumors.

7 Jun 2010

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.

7 Jun 2010

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Microplasmin exhibits potential to cure 50% of patients with macular hole

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that further data from the first successful Phase III trial with microplasmin (TG-MV-006) for the non-surgical treatment of vitreomacular adhesion (VMA) were presented at the World Ophthalmology Congress by Dr. Matthew Benz, MD (The Methodist Hospital, Houston, Texas, U.S.)

7 Jun 2010

CPAP treatment may be a better option for preterm infants

A national study involving a UT Southwestern Medical Center neonatologist provides new insight into how much oxygen preterm infants should receive as well as the optimal way to deliver it to them.

3 Jun 2010

Latinos have highest rates of eye disease: New research

New research suggests Latinos have the highest rates of eye disease in the United States, and one Los Angeles area clinic, Eye Physicians of Long Beach, is supremely prepared to meet the community's eye care needs.

2 Jun 2010

Report: 235 new medicines in development to treat diabetes

A record 235 new medicines to treat diabetes, one of the fastest-growing diseases in America, are being developed by America's pharmaceutical research and biotechnology companies, according to a national report unveiled today in Charleston.

26 May 2010

Significant progress on international development strategy for stem cell-derived human corneal tissue

International Stem Cell Corporation, www.intlstemcell.com, today announced significant progress on its international development strategy for stem cell-derived human corneal tissue. Such tissue can potentially be used to replace cadaver-derived corneas in treatment of severe corneal vision impairment and to eliminate the need to use live animals in safety testing of drugs, chemicals and consumer products.

25 May 2010

Computerized systems can detect early eye problems related to diabetes: UI team

People with diabetes have an increased risk of blindness, yet nearly half of the approximately 23 million Americans with diabetes do not get an annual eye exam to detect possible problems.

13 May 2010

pSivida reports consolidated net loss of $2.7 million for third-quarter 2010

pSivida Corp., a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its third quarter and nine months ended March 31, 2010.

13 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

NEI renews K12 grant for Mass. Eye and Ear to fund Harvard Vision Clinical Scientist Development Program

The Massachusetts Eye and Ear Infirmary, Harvard Medical School Department of Ophthalmology, has been awarded a grant renewal from the National Institutes of Health, National Eye Institute (NEI), to recruit, train and support first-rate clinician scientists to promote translational and clinical research into cures for eye disease.

11 May 2010

Telemedical Retinal Image Analysis and Diagnosis technology permits early detection of diabetic retinopathy

Automated Medical Diagnostics, a startup company based in Memphis, envisions its product helping to preserve the sight of millions of people at risk of vision loss from diabetic retinopathy.

7 May 2010

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

The Burnier International Ocular Pathology Society is holding a Scientific Colloquium in Montreal today to mark the tenth anniversary of the McGill University Health Centre's Henry C. Witelson Ocular Pathology Laboratory. The lab is an internationally reputed centre for the study and treatment of eye diseases and is leading a global network for the sharing of healthcare knowledge and expertise.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

Eye Disease News and Research

Further Reading

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

UH, AOA partner to get the word out about summer eye care, protection against UVR

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Researchers to present advanced treatment strategies for eye diseases at NEI symposium

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

Microplasmin exhibits potential to cure 50% of patients with macular hole

CPAP treatment may be a better option for preterm infants

Latinos have highest rates of eye disease: New research

Report: 235 new medicines in development to treat diabetes

Significant progress on international development strategy for stem cell-derived human corneal tissue

Computerized systems can detect early eye problems related to diabetes: UI team

pSivida reports consolidated net loss of $2.7 million for third-quarter 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

NEI renews K12 grant for Mass. Eye and Ear to fund Harvard Vision Clinical Scientist Development Program

Telemedical Retinal Image Analysis and Diagnosis technology permits early detection of diabetic retinopathy

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News